514 results about "Immune effects" patented technology

The invention relates to the technical field of immunology, and discloses a QS-21 composite adjuvant as well as a preparation method and application thereof, and the QS-21 composite adjuvant comprises the following components in parts by weight: 0.1-0.5 part of QS-21; 4 to 6 parts of liposome; 0.05 to 0.1 part of CpG oligonucleotide; 0.1 to 0.3 part of a freeze-drying protective agent; 0.2 to 0.5 part of a stabilizing agent; 3 to 5 parts of propylene glycol; 1-2 parts of ethanol; 5-15 parts of an organic solvent chloroform; the liposome is prepared from the following components in parts by weight: 3 to 4 parts of phospholipid distearate; and 1-2 parts of amino lipid. By compounding the liposome carrier and the QS-21, adding the CpG oligonucleotide and optimizing the freeze-drying protective agent, the loading efficiency of the immunologic adjuvant, the immune effect stability and the restorability after freeze-drying are improved, and the durability and efficacy of immune response are enhanced.

The invention discloses a monoclonal antibody for distinguishing a hog cholera lapinized virus vaccine strain and a hog cholera lapinized virus epidemic strain and application of the monoclonal antibody, and belongs to the field of immune globulin. The E2 protein monoclonal antibody or the antigen binding fragment thereof comprises a heavy chain variable region (SEQ ID No.1) and a light chain variable region (SEQ ID No.3). The invention also discloses an ELISA method for identifying and distinguishing hog cholera lapinized virus vaccine strains and epidemic strains by using the E2 protein monoclonal antibody. The monoclonal antibody disclosed by the invention has a specific reaction with the swine fever virus epidemic strain and does not react with the swine fever lapinized virus vaccine strain, and the swine fever lapinized virus vaccine strain and the epidemic strain can be accurately identified and distinguished by utilizing an ELISA competition method established by the monoclonal antibody. The monoclonal antibody provided by the invention can be used in the fields of CSFV immunization, serological diagnosis of wild viruses, immune effect evaluation, related experiments and the like, and provides antibody resources for effective detection and purification of CSFV.

The invention discloses an anti-pestivirus broad-spectrum neutralizing monoclonal antibody and application thereof, and belongs to the field of immune globulin. The anti-pestivirus monoclonal antibody or the antigen binding fragment thereof comprises a heavy chain variable region (SEQ ID No.1) and a light chain variable region (SEQ ID No.3). The monoclonal antibody provided by the invention can identify hog cholera virus and all known plague virus members (BVDV1, BVDV2, BDV, HoBiPeV, AydinPeV and OVPV) capable of infecting cattle and sheep at present, has good neutralizing ability, and can be prepared into a diagnostic product for plague virus antigen-antibody detection. The monoclonal antibody and a diagnostic product developed based on the monoclonal antibody can be used for serological diagnosis and immune effect evaluation of pestivirus, pestivirus pathogen detection of experimental serum products and the like, and have wide application prospects in the fields of clinical diagnosis and the like.

The invention discloses a virulence-attenuated bovine nodular skin disease virus LSDV-75 and application thereof, and belongs to the technical field of attenuated strains. The invention aims to provide a bovine nodular skin disease virus vaccine strain which is sufficient in attenuation and good in immune effect. The invention provides a virulence-attenuated bovine nodular skin disease virus strain, which is named as sheep pox virus LSDV-75, has the preservation number of CCTCC NO: V2024114, and is preserved in the China Center for Type Culture Collection on December 2, 2024. The vaccine strain provided by the invention can be used as a vaccine candidate strain for safely and effectively preventing and controlling bovine nodular dermatosis.

The invention belongs to the field of monoclonal antibodies, and particularly relates to a mouse anti-pelteobagrus fulvidraco IgM monoclonal antibody, a hybridoma cell strain secreting the monoclonal antibody and application, a CDR region of a heavy chain variable region of the mouse anti-pelteobagrus fulvidraco IgM monoclonal antibody comprises three sequences shown in SEQ ID NO.1-3, and a CDR region of a light chain variable region of the mouse anti-pelteobagrus fulvidraco IgM monoclonal antibody comprises three sequences shown in SEQ ID NO.4-6; the mouse anti-pelteobagrus fulvidraco IgM monoclonal antibody can be obtained by being secreted by a hybridoma cell strain PFM-1B7C12A1B2 with the preservation number of CCTCC (China Center for Type Culture Collection) NO: C2024234. The mouse anti-pelteobagrus fulvidraco IgM monoclonal antibody provided by the invention can be used for Western blot and ELISA specific detection of IgM in a pelteobagrus fulvidraco secretion form, and can be used for flow cytometry identification of pelteobagrus fulvidraco IgM + B cells. The monoclonal antibody is good in specificity, high in sensitivity and strong in affinity, can be used for structural analysis, immune response level detection and the like of pelteobagrus fulvidraco IgM, and lays a foundation for in-depth study of a pelteobagrus fulvidraco immune system and establishment of a vaccine immune effect evaluation method taking the antibody level as an index.

The invention discloses a virulence-attenuated bovine nodular skin disease virus LSDV DQ and application thereof, and belongs to the technical field of attenuated strains. The invention aims to provide a bovine nodular skin disease virus vaccine strain which is sufficient in attenuation and good in immune effect. The invention provides a virulence-attenuated bovine nodular skin disease virus strain, which is named as sheep pox virus LSDV-DQ, has the preservation number of CCTCC NO: V2024113, and is preserved in the China Center for Type Culture Collection on December 2, 2024. The vaccine strain provided by the invention can be used as a vaccine candidate strain for safely and effectively preventing and controlling bovine nodular dermatosis.

The invention relates to the technical field of HPV therapeutic vaccines, in particular to an MATV51 recombinant adenovirus vector, application, a preparation method and an HPV 16 / 18 / 52 therapeutic vaccine. The MATV51 recombinant adenovirus vector comprises nucleotide sequences used for coding E6 and E7 antigens of HPV16, HPV18 and HPV52, and further comprises a nucleotide sequence used for coding CD40L. A nucleotide sequence of the recombinant adenovirus vector is designed aiming at an HPV16 / 18 / 52E6-E7 protein antigen and contains a nucleotide sequence for coding CD40L, and the expressed fusion protein takes CD40L as an adjuvant; the HPV 16 / 18 / 52 therapeutic vaccine can cover genotypes of three HPV viruses at the same time, and has good immune effect and memory effect, so that the effect of the vaccine is effectively improved, and the application range is wide.

The invention discloses a neurotoxicity-free recombinant live virus vector rabies vaccine, which is prepared by replacing G protein of vesicular stomatitis virus with G protein of HEP-Flury rabies virus strain or G protein mutant of HEP-Flury rabies virus strain, and saving recombinant virus VSV-HEP-Flury by using a reverse genetic manipulation technology. The recombinant live virus vector rabies vaccine has no neurotoxicity after being inoculated. The method is free of neurotoxicity, high in safety, simple in inoculation procedure, good in immune effect and high in productivity.

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody 1D3 for detecting a porcine epidemic diarrhea virus antibody and application of the monoclonal antibody 1D3. The CDR sequences of the heavy chain variable region are respectively shown as SEQ ID NO.1-3, and the CDR sequences of the light chain variable region are respectively shown as SEQ ID NO.4-6. The antibody can specifically recognize PEDV / S1 protein, binding of the antibody can be competitively blocked by a PEDV specific neutralizing antibody in serum, and the antibody is suitable for establishing a blocking ELISA method. A detection tool based on the antibody has high specificity and sensitivity, and the blocking rate to PEDV positive serum is higher than 50%. The invention can be used for preparing a detection kit or evaluating the immune effect of a vaccine, and provides an efficient and accurate technical means for PEDV infection diagnosis and immune monitoring.

The invention belongs to the technical field of biological medicine, and particularly relates to a manganese-doped zeolite imidazole framework and application thereof in tumor radiotherapy. According to the present invention, the new use of the manganese-doped zeolite imidazole framework as the tumor radiosensitizer is found, Mn-ZIF-8 has ray responsiveness, can continuously release Mn < 2 + > ions under X-ray irradiation, and can enhance the activation of a cGAS-STING signal channel so as to promote DCs maturation and antigen presentation, and enhance the T cell mediated immune response, such that the tumor treatment effect is enhanced. Furthermore, the invention provides the Mn-ZIF-8 microneedle, the microneedle has the characteristics of rapid dissolution and controlled release, ensures accurate delivery and continuous action of drugs at tumor sites, reduces systemic toxicity, and can significantly amplify local and systemic immune effects caused by radiotherapy and improve the therapeutic effect when used in combination with an immune checkpoint inhibitor.

The invention belongs to the technical field of biochemical engineering, and particularly relates to an amitriptyline hapten and a preparation method thereof, an amitriptyline antigen and a preparation method thereof, an antibody, a kit and application. The amitriptyline hapten has a structural formula shown as a formula (I) or a formula (II). Compared with an existing structure, the amitriptyline hapten prepared by the invention has a better immune effect. The obtained antibody is high in titer, strong in specificity and high in affinity, the LOD of amitriptyline by using an Elisa method established by the antibody is 0.013 ng / mL, the IC50 of amitriptyline is 0.865 ng / mL, the quantitative detection range is 0.07-470.3 ng / mL, the detection sensitivity is high, and the linear range is wide.

The invention relates to the technical field of immune carrier microspheres, in particular to an immune carrier microsphere constructed by individualized MHC-II combined polypeptide, a vaccine and application of the immune carrier microsphere and the vaccine. A core comprises microspheres constructed by a plurality of MHC-II binding polypeptides, sequences of the MHC-II binding polypeptides are obtained based on HLA gene typing results of an inoculator, and each HLA gene corresponds to at least one high-affinity MHC-II binding polypeptide; a shell is a glucan with sulfydryl or other polymer coating layer, and sulfydryl is used as a coupling group to be connected with an antigen to construct the vaccine. The method has the advantages that competition is avoided, inhibition is generated, a better immune effect is achieved, antibodies of high-titer carrier molecules are not generated, and cross reaction side effects are avoided. The carrier molecular diversity is reduced; side effects are avoided. And antibody immunity and cellular immunity functions are generated. The particle size of the microspheres is controllable, and the immunologic function can be achieved without adjuvants. The preparation process is simple to operate and good in repeatability.

The invention relates to the technical field of biological medicines, in particular to a recombinant rabies virus nano-antibody fused with a solubilizing oligopeptide and a cell penetrating peptide and application of the recombinant rabies virus nano-antibody in preparation of rabies prevention and treatment products. The recombinant rabies virus nano-antibody fused with the solubilizing oligopeptide and the cell penetrating peptide comprises a humanized rabies virus nano-antibody, and the C end of the humanized rabies virus nano-antibody is fused with a solubilizing tag peptide P17 and the cell penetrating peptide. The recombinant rabies virus nano antibody utilizes a prokaryotic expression system, is low in cost, has excellent cell membrane and BBB penetrating ability, can enter a central nervous system from veins for virus neutralization treatment, and has an efficient passive immune effect.

The present invention discloses a vaccine adjuvant, a vaccine composition, and a preparation method and application thereof, relating to the field of veterinary technology. The present invention uses safe, stable, and efficient lipophilic and hydrophilic surfactants, which can reduce the body's side effects and accumulation in the body, and has the technical advantage of high safety. The invention helps to improve the quality of veterinary vaccines and reduce the production costs of veterinary vaccine manufacturers. After the vaccine adjuvant is prepared into a vaccine composition, it can effectively enhance the immunogenicity of the vaccine, improve the vaccine's immune effect, and provide long-term and stable immune protection.

The invention relates to the technical field of mRNA vaccines, and discloses a feline infectious peritonitis mRNA vaccine as well as a preparation method and application thereof. The feline infectious peritonitis mRNA vaccine comprises mRNA molecules; the mRNA molecule comprises an FIBV-S protein coding sequence as shown in SEQ ID NO: 6. According to the invention, the mRNA sequence for coding the natural FIBV-S protein is modified, so that the FIBV-S protein obtained by translation can be stably maintained at the prefusion conformation and has higher immunogenicity, thereby endowing the mRNA vaccine with a better immune effect and being beneficial to the prevention of feline infectious peritonitis.

The invention provides a tumor cell vaccine as well as a preparation method and application thereof. The preparation method comprises the following steps: acquiring and culturing tumor cells; enabling the cell membrane of the tumor cell to express a targeting antibody by utilizing a gene vector infection or gene editing technology, and enabling the targeting antibody to be used for enabling the tumor vaccine to be combined with the dendritic cell; performing overexpression of tumor specific protein on the cell membrane surface of the tumor cell by using a gene vector infection or gene editing technology; a nucleic acid substance of a target protein is wrapped by lipid nanoparticles to form a vaccine framework, and the nucleic acid substance can enable target cells to express directional chemotactic molecules; wherein the directed chemotactic molecule is used for transferring the dendritic cells to lymph nodes; the target vaccine is obtained by wrapping the vaccine framework with the cell membranes of the tumor cells, lymph node homing of the dendritic cells can be promoted, and the antigen presentation efficiency is increased and the immune effect is enhanced through tumor specific protein carried by the target vaccine and assisted by an immunologic adjuvant.

The invention discloses a 5 'UTR and application thereof. A nucleotide sequence of the 5' UTR is selected from a sequence shown in any one of SEQ ID NO.1-6. The 5 'UTR can prolong expression and stability of mRNA (messenger ribonucleic acid) and remarkably improve the immune effect of a vaccine.

The invention belongs to the technical field of biological medicine, and particularly discloses a composite vaccine adjuvant as well as a preparation method and application thereof. The composite vaccine adjuvant provided by the invention is an oil-in-water emulsion, and simultaneously contains squalene, polysorbate 80, sorbitan trioleate, polyinosinic acid (Poly I: C) and CpG oligodeoxynucleotide (CpG-ODN). The sequence-optimized CpG-ODN and Poly I: C are used in a specific emulsion system in a combined mode, a remarkable synergistic immune enhancement effect can be generated, the induced humoral immunity and cellular immunity response level is remarkably higher than the sum of the effects when all the components are independently used, and the composite adjuvant is good in stability, high in immunostimulatory activity and suitable for clinical application. The immune effect can be remarkably improved by combined application with various vaccine antigens. The invention also provides a preparation method and application of the composite vaccine adjuvant.

The invention provides a varicella-zoster virus mRNA (messenger Ribonucleic Acid) vaccine and application thereof. The invention firstly provides an mRNA molecule, a coding region sequence of the mRNA molecule comprises a nucleotide sequence for coding an amino acid sequence as shown in SEQ ID NO: 1, and the coding region sequence preferably comprises a nucleotide sequence as shown in any one of SEQ ID NO: 2 to SEQ ID NO: 11, or a nucleotide sequence which has at least 93% similarity with the nucleotide sequence as shown in any one of SEQ ID NO: 2 to SEQ ID NO: 11 and codes the same amino acid sequence. When the mRNA molecule is used for preparing the vaccine, the production cost of the vaccine can be reduced, the physicochemical property of the vaccine is stable, the protein expression is improved to enhance the immune effect of the vaccine, and the humoral immunity and cellular immunity effects of the VZV-gE specificity are enhanced.

The invention provides a larimichthys crocea iridovirus inactivated vaccine as well as a preparation method and application thereof, and belongs to the technical field of preparation of viral vaccines. The larimichthys crocea iridovirus inactivated vaccine comprises an inactivated larimichthys crocea iridovirus and an adjuvant, and the strain of the larimichthys crocea iridovirus is an FD201807 strain. After the larimichthys crocea iridovirus inactivated vaccine is injected, the phenomena of ingestion and abnormal behaviors of fishes are avoided, the death phenomenon is avoided, the safety is high, the relative immune protection rate of the inactivated vaccine to immunized fishes is 51.20% or above, the immune effect is good, and the larimichthys crocea iridovirus inactivated vaccine can be applied to prevention and treatment of larimichthys crocea iridovirus diseases. The preparation method of the larimichthys crocea iridovirus inactivated vaccine is simple and convenient, easy to operate, low in cost and suitable for industrial production.

The invention discloses an echinococcosis mRNA (messenger Ribonucleic Acid) vaccine as well as a preparation method and application thereof. The preparation method of the mRNA vaccine for the echinococcosis comprises the following steps: carrying out codon optimization on a modified target antigen protein, then assembling the modified target antigen protein with 5 'UTR, 3' UTR and Poly (A) tail, carrying out gene synthesis, then cloning the synthesized gene into a pUC57 plasmid, and sequentially carrying out plasmid linearization, in-vitro transcription and purification on the constructed recombinant plasmid to prepare an mRNA molecule, thereby obtaining the mRNA vaccine for the echinococcosis. Finally, mRNA molecules are wrapped in lipid nanoparticles through a microfluidic method to form the mRNA vaccine for the echinococcosis, and immune effect evaluation is carried out on the mRNA vaccine for the echinococcosis. Experiments prove that the prepared mRNA vaccine for the echinococcosis can activate humoral immunity and cellular immunity of mice at the same time, can provide an effective protection effect for the mice attacking insects, and has a wide application prospect in the aspect of preventing and / or treating the echinococcosis.

The present invention provides a tumor neoantigen vaccine system specifically marking a heterologous protein, and a use thereof. The vaccine system is composed of a heterologous protein mRNA vaccine and a recombinant oncolytic virus; the heterologous protein mRNA vaccine is used to induce an organism to generate heterologous protein-specific memory T cells, and the recombinant oncolytic virus is used to promote a tumor to express microorganism-derived tumor neoantigens. When pre-immunized memory T cells detect these marked specific neoantigens, the tumor expressing the neoantigens is quickly activated and killed, the release of tumor autoantigens is promoted, dendritic cells phagocytize antigens to further initiate an anti-tumor response, and a systemic anti-tumor immune effect is activated by means of antigenic epitope spreading.

The present invention relates to CpG oligodeoxyribonucleotides with improved body immunity, combinations thereof with additional adjuvants, and uses of the CpG adjuvants or combinations thereof in various vaccine compositions. The CpG independently serves as an adjuvant or is combined with an existing marketed adjuvant for use, and the CpG has the very remarkable advantages that the immune effect is advanced, the immune effect is improved, the lasting period of the immune protection effect is longer, the potential anaphylactic reaction is lower and the like, is superior to a commercially available vaccine adjuvant or an adjuvant system, and is a very excellent effective component of the vaccine adjuvant or the vaccine adjuvant system.

The invention relates to a monoclonal antibody DIDA55 aiming at hog cholera virus, and a preparation method and application thereof, belonging to the field of medical preparations. The monoclonal antibody DIDA55 or an antigen binding fragment thereof comprises a heavy chain variable region and a light chain variable region, amino acid sequences of LCDR1, LCDR2 and LCDR3 in a light chain variable region of the antibody are shown as 24th to 34th, 50th to 56th and 89th to 97th in SEQ ID No: 4; amino acid sequences of HCDR1, HCDR2 and HCDR3 in a heavy chain variable region of the antibody are shown as the 31st to 35th, the 50th to 65th and the 95th to 102th of SEQ ID No: 5. The monoclonal antibody provided by the invention can be used in the fields of swine fever E2 protein labeled subunit vaccine immunity, serological diagnosis of wild strains, swine fever vaccine immune effect evaluation, related experiments and the like, and provides antibody resources for prevention, control and purification of CSF.

The invention relates to the technical field of biological medicines, in particular to a vaccine for treating or preventing hepatitis B virus infection. The vaccine comprises a hepatitis B surface antigen and a composite adjuvant, wherein the composite adjuvant is prepared from CpG oligodeoxynucleotide and saponin QS-21, and the composite adjuvant is prepared from CpG oligodeoxynucleotide and saponin QS-21; the nucleotide sequence of the CpG oligodeoxynucleotide is as shown in SEQ ID NO. 1. According to the vaccine provided by the invention, an HBsAg antibody can be generated in a normal mouse body, and HBV in an HBV-carrier mouse can be effectively eliminated, so that the vaccine has the effect of treating or preventing hepatitis B virus infection. According to the vaccine provided by the invention, two adjuvants, namely CpG oligodeoxynucleotide and saponin QS-21, are adopted, so that the vaccine can be used for synergistically activating an immune effect, enhancing the activation of B cells and permanently transforming into plasma cells, and meanwhile, the vaccine can be used for resisting immune tolerance of T cells, realizing the removal of hepatitis B viruses and realizing functional cure of clinical hepatitis B treatment.

Provided are a vaccine for preventing feline herpesvirus infection, and a preparation method therefor and the use thereof. By means of antigen sequence design and screening, an antigen peptide and an mRNA nucleic acid molecule having excellent expression effects are obtained, and thus a vaccine prepared therefrom has a good immune effect and can induce the production of a highly-effective and durable level neutralizing antibody against a feline herpesvirus at a very low dose and dosing regimen; meanwhile, the mRNA vaccine has the characteristics of a good stability, a high delivery efficiency, safety, effectiveness and a controllable quality.

The invention discloses a dual-targeting macrophage membrane nano system and a preparation method and application thereof, and belongs to the field of biological medicine, MKA is wrapped in a macrophage membrane after AuNPs and mitochondrial targeting peptide KLA are connected. The preparation method comprises the following steps: firstly synthesizing AuNPs and modifying, and then wrapping with a macrophage membrane. In treatment, the compound can realize double targeting of tumor cells and mitochondria, enhance radiation-induced DNA damage, inhibit DDR, activate immune pathways and promote T cell infiltration, and can also consume glutathione and amplify oxidative stress to enhance immune effect, and the dose enhancement ratio of the compound in cooperation with 8GyX-rays reaches 3.1. In addition, the MKA is good in biocompatibility in vivo, long in blood circulation time, high in tumor targeting and capable of being quickly cleared through the kidney. The invention provides a new way for tumor radioimmunotherapy, and is helpful for promoting the progress of clinical tumor treatment.

The invention discloses an aggregation-induced emission photosensitizer, a pharmaceutical composition constructed by the aggregation-induced emission photosensitizer, a preparation method and application of the aggregation-induced emission photosensitizer. The aggregation-induced emission photosensitizer MTCN-3 has excellent active oxygen generation capability and photothermal effect, and plays a dual effect of inducing pyroptosis and ferroptosis of tumor cells. The aggregation-induced emission photosensitizer and an immune agonist Poly (I: C) can play a photoimmune synergistic effect, and a co-assembled pharmaceutical composition has a near-infrared aggregation-induced emission effect, is good in subcellular distribution and has active targeting selectivity on tumor cells; tumors are eliminated and tumor metastasis is prevented by preventing immune escape, growth of primary tumors and far-end tumors is inhibited, and the systemic anti-tumor immune effect is achieved; stability is good, toxic and side effects are low, and clinical application prospects are wide. # imgabs0 #

The invention is applicable to the technical field of biomedicine, and provides a preparation method and application of a multifunctional nano composite material. The material has good biocompatibility and can be used as a safe preparation for tumor treatment; the preparation is simple, green and pollution-free; the application of the quercetin in anti-tumor immunotherapy is expanded; the probe has excellent fluorescence / computed tomography dual-mode imaging performance, and can be used for determining tumor boundaries and realizing accurate treatment guidance; the nano-material has excellent photo-thermal and photo-thermal enhanced catalytic performance, has the advantages of being minimally invasive, efficient, small in toxic and side effect, controllable and the like, and can effectively treat primary, metastatic or recurrent head and neck squamous cell carcinoma by activating immunity; by inducing tumor cells to release 2 '3'-cGAMP and preventing the 2 '3'-cGAMP from being degraded, a cGAS-STING signal channel is efficiently activated, and finally the anti-tumor immune effect is enhanced.

The invention provides synthesis of a T-2 toxin antigen and preparation and application of a monoclonal antibody. Relates to the technical field of biotoxin detection. The preparation method of the T-2 toxin antigen comprises the following steps: step 1, synthesizing an immunogen T-2-BSA by adopting a carbodiimide method, dissolving 2mg of T-2 adipic acid with 0.5 mL of dimethylformamide, and recording as a solution A; 5 mg of bovine serum albumin and 3 mg of EDC are dissolved with a 2-morpholine ethanesulfonic acid buffer solution with the pH being 5.5, and the solution is marked as a solution B; step 2, under the condition of stirring, dropwise adding the solution A into the solution B, stirring for 18 hours in a dark place at 4 DEG C, then dialyzing for 3 days by using a phosphate buffer solution, changing the solution once a day, centrifuging the dialysate for 10 minutes at 3,500 r / min, and discarding the precipitate; the adipic acid is coupled with the T-2 toxin through a chemical method, and the unique step enriches the structural characteristics of the hapten, so that the prepared T-2 toxin complete antigen is excellent in immune effect, can efficiently excite immune response of an organism, and shows high specificity and sensitivity.